Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Production and application of recombinant extracellular vesicles for method development, data normalization and assessment of pre-analytical variables

ABSTRACT: The diagnostic and therapeutic use of extracellular vesicles (EV) is under intense investigation and may lead to societal benefits. Reference materials are an invaluable resource for developing, improving and assessing the performance of regulated EV applications and for quantitative and objective data interpretation. We have engineered recombinant extracellular vesicles (rEV) as a biological reference material. rEV have similar biochemical and biophysical characteristics as sample EV and function as an internal quantitative and qualitative control throughout analysis. Spike-in applications of rEV in bodily fluids prior to EV analysis map technical variability of EV applications and promote intra and inter laboratory studies. This protocol describes the production, recovery and quality assurance of rEV, their dilution and addition to bodily fluids, and the detection steps based on fluorescence-, nucleic acid- and protein measurements. Multiple application potentials for rEV are exemplified, including method development, big data normalization and assessment of pre-analytical variables. The protocol can be adopted by researchers with standard laboratory and basic EV separation/characterization experience and requires ~4–5 d.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine, Blood Plasma, Extracellular Vesicle

SUBMITTER: Pekka Rappu

LAB HEAD: Olivier De Wever

PROVIDER: PXD017542 | Pride | 2023-03-13

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	200123_EG_A_1.raw	Raw
	200123_EG_A_2.raw	Raw
	200123_EG_A_3.raw	Raw
	200123_EG_B_1.raw	Raw
	200123_EG_B_2.raw	Raw

Items per page:

1 - 5 of 75

Similar Datasets

Benchmarking blood collection tubes and processing intervals for extracellular vesicle performance metrics

Project description:Extracellular vesicle (EV) analysis from blood samples is under intense investigation and holds the potential to deliver clinically meaningful biomarkers for health and disease. Technical variation must be minimized to confidently assess EV-associated biomarkers but the impact of pre-analytics on EV characteristics in blood samples remains minimally explored. We present the results from the first large-scale EV Blood Benchmarking (EVBB) study in which we systematically compared 11 blood collection tubes (BCT; 6 preserving and 5 non-preserving) and 3 blood processing intervals (BPI; 1h, 8h and 72h) on defined performance metrics (n=9). The EVBB study identifies a significant impact of multiple BCT and BPI on a diverse set of metrics reflecting blood sample quality, ex-vivo generation of blood-cell derived EV, EV recovery and EV-associated molecular signatures. The results assist the informed selection of the optimal BCT and BPI for EV analysis. The proposed metrics serve as a platform to guide future research on EV pre-analytics and further support methodological standardization of EV studies.

2023-03-13 | PXD035199 | Pride

Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine

Project description:Mass spectrometry-based proteomic analysis of urinary EV (uEV) in men with benign and malignant prostate disease, profiling the proteome of EV separated from prostate tumor interstitial fluid and matched uEV, and a comparative proteomic analysis with uEV from patients with bladder and renal cancer.

2020-04-09 | PXD015289 | Pride

Growth media conditions influence the secretion route and release levels of engineered extracellular vesicles

Project description:Extracellular vesicles (EVs) are nanosized cell-derived vesicles found in all bodily fluids which provide a route of intercellular communication by transmitting biological cargo. While EVs offer promise as therapeutic agents, the molecular mechanisms of EV biogenesis are not yet fully elucidated, in part due to the concurrence of numerous interwoven pathways which give rise to heterogenous EV populations in vitro. The effects of conditions in the cellular environment on EV production are of particular interest. In this study, we utilize a quantifiable EV-engineering approach to investigate how various cell media conditions alter EV production. The presence of serum, exogenous EVs, and other signaling factors in cell media alters EV production on physical, molecular, and transcriptional levels. Further, we demonstrate that exosome biogenesis pathways are the major factors contributing to EV production under optimized conditions. Our findings suggest a novel understanding to the mechanisms underlying EV production in cell culture which can be applied to develop advanced EV production methods.

2021-04-29 | GSE173474 | GEO

Recombinant extracellular vesicles as a biological reference material

Project description:Recent years have seen a tremendous increase in the study of extracellular vesicles (EV) geared towards biological understanding, diagnostics and therapy. The interpretation of EV data however remains challenging owing to the complexity of biofluids and the technical variability that are introduced during sample preparation. To understand and mitigate these errors we present the use of traceable recombinant EV (rEV) that mimic endogenous EV both physically and biochemically. The informed use of rEV ensures standardized measurements in various research and biomedical applications. In this dataset we performed mass spectrometry-based proteomics analyses to compare the protein content of endogenous EVs (eEV) and traceable recombinant EV (rEV). The analysis showed that both types of EVs are very similar and that more than 90% of proteins are equally abundant in rEV and eEV isolated from HEK293T cells.

2019-07-11 | PXD010269 | Pride

The overall response of Paenibacillus larvae to bodily fluids of honeybee larvae (Apis mellifera).

Project description:Paenibacillus larvae, the causal agent of American Foulbrood disease (AFB), affects honeybee health worldwide. The present study investigates the transcriptional response of this Gram-positive, endospore-forming bacterium to bodily fluids from honeybee larvae. Four different conditions were evaluated with a loop design: sampling of in vitro grown P. larvae cultures one or four hours after addition of larval fluids or BHIT-broth (C1, T1, C4, T4).

2014-12-22 | GSE37481 | GEO

Comparison of performances of automatic versus manual liquid handling in density-based separation of extracellular vesicles from plasma and urine

Project description:Extracellular vesicles (EV) in body fluids are extensively studied as potential biomarkers for numerous diseases. Major impediments of EV-based biomarker discovery include the manual labor, and the specificity and reproducibility of EV sample preparation. To tackle this, we present an automated liquid handling workstation for the density-based separation of EV from human body fluids and compare its performance to manual handling by (in)experienced researchers. To validate automated density-based separation of EVs from human body fluids, including blood plasma and urine, we assess variation, yield and purity by mass spectrometry-based proteomics.

2023-05-10 | PXD032394 | Pride

Spatial extracellular vesicle microRNA profiles in ovarian cancer

Project description:We newly invented the EV sheet, which is a unique nanofiber paper to capture extracellular vesicles from around 10 uL of bio-fluids. In this study, we investigated miRNA profiles of tumor-surface ascites, serum, and urine using the EV sheet.

2023-10-03 | GSE216745 | GEO

cirDNA methylome analysis in prostate cancer

Project description:DNA modification profiling of circulating DNA (cirDNA) from plasma samples from prostate cancer patients (T2-3N0Mx), benign prostatic hyperplasia and control individuals Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers.

2012-07-10 | GSE36195 | GEO

Identification of novel long non-coding RNAs as biomarker for patients with renal cell carcinoma

Project description:Long non-coding RNAs (lncRNA) play an important role in carcinogenesis, but knowledge of lncRNA expression in renal cell carcinoma is rudimental. We screened 32,183 lncRNA transcripts in malignant and adjacent normal renal tissue and determined dysregulation of approximately 4% of the lncRNA transcripts in clear cell renal cell carcinoma tissue. The distinct changes of lncRNA expression may be used to develop a non-invasive biomarker, because lncRNAs are detectable in bodily fluids. Microarray experiments were performed to determine the expression of 32,183 lncRNA transcripts belonging to 17,512 lncRNAs in 15 corresponding normal and malignant renal tissues

2015-02-18 | E-GEOD-61763 | biostudies-arrayexpress

‘Shotgun’ Proteome Analyses Do Not Require Alkylation of Cysteine

Project description:It is a common belief that reduction of disulfide bridges and alkylation of thiols in proteins are indispensable steps in proteomic sample preparation. Since this chemical procedure is often incomplete and prone to side reactions and can results in various artefacts we reexamined its importance. We found that the reduction and alkylation do not increase the depth of analysis and quality of proteomic quantification therefore these steps are unessential in shotgun-type investigations of proteomes. Moreover, we found that compared to a standard procedure using iodoacetamide for thiol-alkylation, sample preparation under conditions protecting thiols from oxidation improves quality of peptides and allows identifying of 10-20% more peptides and proteins. Excluding the thiol-alkylation from proteomic sample preparation, shorten the workflows, and decreases the probability of biases resulting from occurrence of artificially modified peptides.

2020-01-21 | PXD014000 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data